Fig 1: KPNA1 is not required for EBV entry into NOK cells.a. Immunoblot analysis of KPNA1 expression in WCL lysates of Cas9+ NOK with the indicated sgRNAs.b-c. KPNA1 is dispensable for NOK cell EBV infection. Control or KPNA1 KO NOK-Cas9+ cells were co-incubated with cell free EBV at a MOI of 200 - 400 Green Daudi Units (GDUs) for 3 hours at 37°C. eGFP+ cell percentages were quantitated by FACS 72 hours later. (b) Representative FACS images. (c) Mean ± SEM eGFP+ cell percentages from n=3 reps, as in (b). d-e. KPNA1 is dispensable for B cell to epithelial cell EBV spread. Control or KPNA1 KO NOK were cocultured with anti-human-IgG treated Akata-EBV+eGFP cells for 48 hours. NOK cell EBV infection was analyzed by FACS at 48 hours post-infection. (d) Representative FACS histograms. (e) Mean ± SEM NOK cell GFP+ cell percentages from n=3 reps, as in (d).
Fig 2: KPNA1 is dispensable for EBV replication in B cells.a. Immunoblot analysis of KPNA1 expression in WCL form Cas9+ Akata cells with control or KNPA1 sgRNAs, mock induced or induced for EBV reactivation by treatment with goat-anti-human-IgG for 24 hours.b-c. KPNA1-KO does not affect eGFP transgene expression in reactivated Akata (EBV+eGFP) cells. (b) Shown are representative FACS plots of GFP expression at 24 hours of mock treatment or goat-anti-human-IgG cross-linking. eGFP expression increases in lytic Akata EBV+eGFP cells. Representative histograms from n=3 replicates are shown. (c) Mean ± SEM eGFP+ cell percentages from n=3 replicates, as in (b).d-e. Akata (EBV+eGFP) cell KPNA1-KO does not affect EBV spread to B cell targets. Daudi B cell targets were co-incubated with supernatant from control or KPNA1 KO goat-anti-human-IgG cross-linked Akata (EBV+eGFP) cells, as in (a). Daudi eGFP expression was analyzed by FACS at 24 hours post-co-culture. Representative FACS histograms from n=3 replicates are shown. (d) Representative FACS histograms. (e) Mean ± SEM Daudi cell GFP+ cell percentages from n=3 reps, as in (d).f-g. Akata (EBV+eGFP) cell KPNA1-KO does not affect EBV spread to epithelial cell targets. NOK cell targets were co-incubated with supernatant from control or KPNA1 KO goat-anti-human-IgG cross-linked Akata (EBV+eGFP) cells, as in (a). NOK GFP expression was analyzed by FACS at 24 hours post-co-culture. Representative FACS histograms from n=4 replicates are shown. (f) Representative FACS histograms. (g) Mean ± SEM NOK cell GFP+ cell percentages from n=3 reps, as in (f).Data represent mean ± SEM from three biological replicates. Two-sided unpaired Mann-Whitney test ***P < 0.001 and *P<0.05). ns, not significant.
Fig 3: KPNA1 KO does not induce innate immune responses during EBV infectiona-b, KPNA1 KO does not promote IFNB or OAS1 mRNA expression in Daudi B cells.Control or KPNA1 KO Daudi cells were co-cultured with EBV at a MOI of 1.0 for 3 hours at 37°C. After 24 hours, mRNA levels of IFNB (a) and OAS1(b) were analyzed by real-time PCR. GAPDH was used as an internal control.Data represent mean ± SEM from three biological replicates. Two-sided unpaired Mann-Whitney test ***P < 0.001 and **P<0.01). ns, not significant.
Fig 4: KPNA1 is required for EBV B cell infection.a. Immunoblot analysis of WCE from Daudi cells that expressed control or two independent CD81 targeting sgRNA.b-c. KPNA1 KO impaired EBV infection of Daudi B cells. Control or KPNA1 KO Daudi cells were co-incubated with EBV at a MOI of 1.0 for 3 hours at 37°C. The percentage of eGFP-positive infected cells was analyzed 24 hours post-infection using FACS. Representative histogram images of FACS were shown. c. Mean ± SEM % eGFP+ cells from n=3 replicates as in (b).d. The expression levels of PM CD81, CD19, HLA-DR and CD21 are similar in control versus KPNA1 KO Daudi cells. Cas9+ Daudi cells that expressed control or KPNA1 targeting sgRNAs were anaylzed by FACS.e. Analysis of KPNA1 expression in KPNA1-KO Daudi cells with KPNA1 cDNA rescue. Shown are immunoblots from WCL prepared from KPNA1-KO Daudi with stable mCherry (control) or CRISPR resistant KPNA1 (resistant to sgKPNA1#1) cDNAs.f-g. KPNA1 rescue restored EBV infection in Daudi-Cas9 cells. KPNA1-KO Daudi-Cas9 as in (e) were co-incubated with EBV at a MOI of 1.0 for 3 hours at 37°C. The percentages of eGFP-positive infected cells were analyzed 24 hours post-infection by FACS. The percentages of eGFP+ (EBV-infected) Daudi B cells expressing sgRNA control (sgCTL) and mCherry were set to 100. (g) Representative microscopy images of Cas9+ Daudi cells with the indicated sgRNA and rescue cDNA expression as in (e). Scale bar: 150μm.Data represent means ± SEM from three biological replicates. two-sided unpaired Mann-Whitney test (***P < 0.001 and **P<0.01). ns, not significant.
Supplier Page from DNASU for KPNA1 (Homo sapiens) in pDONR221 (Gateway donor/master vector)